Regarding CLL activation induced by activated T cells, the fact that both SPHK inhibitors similarly reduced the upregulation of the activation markers CD86, PD-1 and PDL1 induced by the presence of activated T lymphocytes, suggests that SPHK2 might participate in the upregulation of these molecules. The gene discussed is SPHK2; the disease is B-cell chronic lymphocytic leukemia.